Micron Is Down 42%, Why It Might Be a Screaming Buy?
Micron Technology (NASDAQ: MU) is no stranger to volatility, but its recent price action has been brutal even by semiconductor standards. Since peaking in June of last year, the stock has tumbled 42%. And nearly 30% of that decline happened in just the past month.
So, is this a falling knife or an undervalued gem in the chip sector?
» Read more about: Micron Is Down 42%, Why It Might Be a Screaming Buy? »
Read More
1 ETF Set To Beat The Market in 2025?
2024 was another banner year for the US stock market, with the S&P 500 notching a gain of 23%. Dwarfing even this return, though, was that of the Financial Select Sector SPDR ETF (XLF), which has delivered a 29.7% return over the last 12 months.
There is lots of speculation that the new President will be supportive of the financial sector so can XLF beat the market again in 2025,
» Read more about: 1 ETF Set To Beat The Market in 2025? »
Read More
1 Rare Stock Buffett Is Buying
Warren Buffett has spent 2024 stockpiling cash, even going so far as to sell off sizeable pieces of some of his largest investments. Recently, though, Berkshire Hathaway announced that it had made some modest acquisitions, including the addition of nearly 388,000 shares of domain name registry service Verisign (NASDAQ:VRSN).
These purchases brought Berkshire Hathaway’s holdings in Verisign to 13.2 million shares,
» Read more about: 1 Rare Stock Buffett Is Buying »
Read More
Massive Upside In Big Money Pharma Favorite?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes in the use of immune therapies for cancer treatment. Specifically, Iovance is exploring new applications of tumor infiltrating lymphocyte (TIL) therapy, utilizing cells that the human body naturally produces to attack cancerous tumors.
There was lots of hype about this next-generation cancer treatment company but its share price has been decidedly lackluster this year,
» Read more about: Massive Upside In Big Money Pharma Favorite? »
Read More
Cyber Woes Crushed This Stock But Growth Story Still Intact
HealthEquity (NASDAQ:HQY) is a fintech company that acts as an administrator of health savings accounts. It’s the largest HSA custodian in the United States and has seen its stock price move rapidly upward over the last five years as these plans became more popular.
That run, however, has abruptly reversed in recent weeks.
» Read more about: Cyber Woes Crushed This Stock But Growth Story Still Intact »
Read MoreThe Ivy
Could Meta Be the Next $2 Trillion Titan?
With over 3.4 billion people engaging with at least one of Meta’s apps daily, the company already owns the world’s largest digital attention network. But now, it’s not just about scale, it’s about intelligence. Meta has embedded AI deep into its core product experiences, reshaping how users interact with content and how advertisers connect with audiences.
» Read more about: Could Meta Be the Next $2 Trillion Titan? »
Read MoreThe Spotlight
This $1 Billion Surprise Just Changed Everything for GEO Stock
While earnings appeared mixed at first glance, management’s comments on the most recent earnings call were sufficient to ignite a sharp rally in GEO shares.
Prior to the earnings call, GEO stock had been in a sustained downtrend with little cushion on the horizon ready to halt the decline but that all changed when management revealed a new,
» Read more about: This $1 Billion Surprise Just Changed Everything for GEO Stock »
Read MoreThe Daily
3 reasons why Warren Buffett doesn’t buy REITs, but here’s why that shouldn’t stop you
Warren Buffett, the Oracle of Omaha, famously steers clear of Real Estate Investment Trusts (REITs). While REITs have long been a proven way for investors to access real estate returns with liquidity and diversification, Buffett’s massive Berkshire Hathaway empire holds barely any REIT exposure. But his avoidance doesn’t mean REITs aren’t worth your attention.